Cailin Conner

DocwireNews

According to a study in <a href="https://rmdopen.bmj.com/content/9/4/e003725" target="_blank" rel="noopener">RMD Open</a>, &ldquo;In patients with DECT [dual-energy computed tomography]-measured MSU [monosodium urate] crystal deposition, reaching the &lt;5.0&thinsp;mg/dL SU [serum urate] target provides more extensive and rapid crystal dissolution than reaching the &lt;6.0&thinsp;mg/dL SU target.&rdquo;Investigators examined 62 patients diagnosed with gout who underwent baseline DECT scans of their knees and feet to measure MSU crystal volumes of at least 0.1 cm&sup3;. These patients also had at least 1 follow-up DECT scan conducted at 6, 12, 18, or 24 months. The primary objective was to examine the relationship between the change in MSU crystal volume and SU levels. The researchers utilized Spearman&rsquo;s correlation coefficient and linear mixed models to assess these associations.Investigators found that the achievement of SU target levels played a significant role in the kinetics of MSU crystal dissolution. A strong correlation was observed between SU levels and the percentage change in MSU crystal volume, highlighting the importance of SU reduction as a therapeutic strategy.Furthermore, the data revealed that patients who reached the lower SU target of &lt;5.0 mg/dL exhibited more extensive and rapid crystal dissolution compared with those who achieved &lt;6.0 mg/dL. At the 12-month mark, the median decrease in MSU crystal volume for patients achieving &lt;5.0 mg/dL was a remarkable &#8210;85%, whereas it was &#8210;40% for those reaching &ge;5.0 mg/dL to &lt;6.0 mg/dL levels.In a multivariable analysis, 3 key factors were identified as significantly associated with MSU crystal volume change: time from the baseline DECT scans, hypertension, and SU level &lt;5.0&thinsp;mg/dL.Time (assessed in days) was inversely associated with crystal dissolution, with shorter time periods associated with more rapid dissolution. Patients with hypertension exhibit slower crystal dissolution. Finally, achieving an SU level of &lt;5.0 mg/dL had a substantial negative coefficient, reinforcing its importance as a target in gout management.

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Latest News

Lower Serum Urate Target Enhances Crystal Dissolution in DECT-Measured MSU Crystal Deposition

Gout

A recent study utilizing DECT showed that achieving a lower serum urate target of &lt;5.0 mg/dL leads to more extensive and rapid dissolution of MSU crystals.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe